SEC Form 4 · accession 0001209191-17-015835
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D Casey
Director
Period of report
Feb 27, 2017
Accepted (ET)
Mar 1, 2017 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 27, 2017 | M | 7,500 | $25.58 | A | 7,500 | D | |
| Common StockF1 | Feb 27, 2017 | S | 7,500 | $121.55 | D | 0 | D | |
| Common StockF2 | holding | — | — | — | 91,362 | I | Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4,F3 | $25.58 | Feb 27, 2017 | M | 7,500 | D | — | Mar 15, 2017 | Common Stock | 7,500 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $121.48 to $121.61, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- F2The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F3The option was fully exercisable.
- F4The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.